Sonova (OTCMKTS:SONVY) Reaches New 52-Week High – Should You Buy?

Sonova Holding (OTCMKTS:SONVY)’s stock price hit a new 52-week high on Monday. The company traded as high as $67.13 and last traded at $67.13, with a volume of 2,322 shares traded. The stock had previously closed at $66.33.

Wall Street Analysts Forecast Growth

SONVY has been the topic of a number of research analyst reports. Citigroup reiterated a “sell” rating on shares of Sonova in a research note on Friday, July 24th. Morgan Stanley upgraded Sonova from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, June 23rd. The Goldman Sachs Group upgraded Sonova from a “hold” rating to a “buy” rating in a research report on Thursday, October 8th. Finally, UBS Group raised Sonova from a “hold” rating to a “buy” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sonova presently has a consensus rating of “Moderate Buy”.

Sonova Trading Up 0.7%

The company has a current ratio of 1.75, a quick ratio of 1.43 and a debt-to-equity ratio of 0.51. The business has a fifty day moving average of $59.41 and a 200-day moving average of $52.91.

About Sonova

Sonova Holding AG is a Switzerland-based hearing-care company that develops, manufactures and distributes solutions for people with hearing loss. Its portfolio includes hearing aids, cochlear implants, hearing implants, wireless communication products and related accessories and services.

The company markets products under several brands, including Phonak, Unitron and Advanced Bionics. Sonova also operates hearing-care businesses and retail networks that provide hearing assessments, device fitting, rehabilitation support and after-sales services.